Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma

被引：6

作者：

Nakanishi, Keita ^{[1
]}

Sakakura, Noriaki ^{[1
]}

Matsui, Takuya ^{[1
]}

Ueno, Harushi ^{[1
]}

Nakada, Takeo ^{[1
]}

Oya, Yuko ^{[2
]}

Shimizu, Junichi ^{[2
]}

Hida, Toyoaki ^{[2
]}

Hosoda, Waki ^{[3
]}

Kuroda, Hiroaki ^{[1
]}

机构：

[1] Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi, Japan

[2] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan

[3] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan

来源：

ANTICANCER RESEARCH | 2019年 / 39卷 / 10期

关键词：

Lung cancer; pulmonary pleomorphic carcinoma; surgery; PD-L1; CELL-CARCINOMA; SPINDLE-CELL; LUNG; CHEMOTHERAPY; MUTATION;

D O I：

10.21873/anticanres.13782

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Pulmonary pleomorphic carcinoma (PPC) is rare, and few studies have reported its features. We assessed the clinicopathological features, surgical outcomes, oncogenic status and programmed death-ligand 1 (PD-L1) expression of PPC. Patients and Methods: We retrospectively reviewed data from 22 consecutive patients who underwent resection of PPC between 2007 and 2017. Results: The predominant tissue type of the epithelial component was adenocarcinoma in 15 patients (68%) and the others in 7 patients (32%), and the 3-year disease-free survival rate tended to be better in patients with an adenocarcinoma component compared to patients with another component (40.0% vs. 17.1%, p=0.059). PD-L1 expression was observed in all eight tumors whose PD-L1 status could be examined and high PD-L1 expression (>= 50%) was frequent (5/8, 63%). Conclusion: A predominant adenocarcinoma epithelial component in PPC might be associated with better survival outcomes and high PD-L1 expression might be frequent in PPC.

引用

页码：5789 / 5795

页数：7

共 50 条

[21] Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies [J].

Tan, Zhaoli ;

Yue, Chunyan ;

Ji, Shoujian ;

Zhao, Chuanhua ;

Jia, Ru ;

Zhang, Yun ;

Liu, Rongrui ;

Li, Da ;

Yu, Qian ;

Li, Ping ;

Hu, Zhiyuan ;

Yang, Yanlian ;

Xu, Jianming .

ONCOLOGIST, 2021, 26 (12) :E2227-E2238

[22] Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer [J].

Chueh, Anderly C. ;

Liew, Mun-Sem ;

Russell, Prudence A. ;

Walkiewicz, Marzena ;

Jayachandran, Aparna ;

Starmans, Maud H. W. ;

Boutros, Paul C. ;

Wright, Gavin ;

Barnett, Stephen A. ;

Mariadason, John M. ;

John, Thomas .

ONCOTARGET, 2017, 8 (43) :74036-74048

[23] PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma [J].

Okadome, Kazuo ;

Baba, Yoshifumi ;

Yasuda-Yoshihara, Noriko ;

Nomoto, Daichi ;

Yagi, Taisuke ;

Toihata, Tasuku ;

Ogawa, Katsuhiro ;

Sawayama, Hiroshi ;

Ishimoto, Takatsugu ;

Iwatsuki, Masaaki ;

Iwagami, Shiro ;

Miyamoto, Yuji ;

Yoshida, Naoya ;

Watanabe, Masayuki ;

Komohara, Yoshihiro ;

Baba, Hideo .

CANCER SCIENCE, 2022, 113 (02) :399-410

[24] Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma [J].

Okada, Satoru ;

Itoh, Kyoko ;

Ishihara, Shunta ;

Shimada, Junichi ;

Kato, Daishiro ;

Tsunezuka, Hiroaki ;

Miyata, Naoko ;

Hirano, Shigeru ;

Teramukai, Satoshi ;

Inoue, Masayoshi .

SURGICAL ONCOLOGY-OXFORD, 2018, 27 (02) :259-265

[25] High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma [J].

Kandl, Thomas J. ;

Sagiv, Oded ;

Curry, Jonathan L. ;

Ning, Jing ;

Ma, Junsheng ;

Hudgens, Courtney W. ;

Van Arnam, John ;

Wargo, Jennifer A. ;

Esmaeli, Bita ;

Tetzlaff, Michael T. .

ONCOIMMUNOLOGY, 2018, 7 (09)

[26] Clinicopathological and prognostic significance of PD-1/PD-L1 axis expression in patients with tongue squamous cell carcinoma [J].

Huang, Weilun ;

Zhou, Xiao ;

Liao, Qianjin ;

Tang, Yanyan ;

Zuo, Liang ;

Wang, Honghan ;

Chen, Xing ;

Chen, Xiaoyan ;

Li, Junjun ;

Zhu, Songlin ;

Deng, Jun ;

Liu, Yan ;

Zhu, Kunjie ;

Yu, Jianjun ;

Xiong, Wei .

JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (10) :6942-6953

[27] Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas [J].

Zhang, Yifan ;

Chen, Yi ;

Papakonstantinou, Andri ;

Tsagkozis, Panagiotis ;

Linder-Stragliotto, Christina ;

Haglund, Felix .

BIOMOLECULES, 2022, 12 (02)

[28] PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions [J].

Lee, Sun Mi ;

Sung, Chang Ohk .

PANCREATOLOGY, 2021, 21 (05) :920-927

[29] PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes [J].

Zhou, Yajuan ;

Miao, Jingjing ;

Wu, Haijun ;

Tang, Hao ;

Kuang, Jing ;

Zhou, Xiaoyi ;

Peng, Yi ;

Hu, Desheng ;

Shi, Dingbo ;

Deng, Wuguo ;

Cao, Xinyue ;

Zhao, Chong ;

Xie, Conghua .

ONCOTARGET, 2017, 8 (31) :51210-51223

[30] PD-L1 expression in large cell neuroendocrine carcinoma of the lung [J].

Eichhorn, F. ;

Harms, A. ;

Warth, A. ;

Muley, T. ;

Winter, H. ;

Eichhorn, M. E. .

LUNG CANCER, 2018, 118 :76-82

← 1 2 3 4 5 →